Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.

Trial Details

NCT ID

NCT04472767

Phase

PHASE2

Sponsor

University of California, Irvine

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

Nivolumab
Ipilimumab
Cabozantinib
Transarterial Chemoembolization

Locations (sample)

Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

Histologic or radiographic diagnosis of hepatocellular carcinoma
At least one lesion amenable to TACE treatment
Child-Pugh A-B7 (B7 based on Albumin allowed)
Not a candidate for resection or transplantation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →